Gland Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.7 pts less than Nifty Smallcap 250 and 2.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Gland Pharma's Board approved unaudited results for Q2 and H1 FY26 (ended September 30, 2025), reviewed by Deloitte Haskins & Sells with an unmodified opinion. Consolidated revenue grew about 6% YoY to ₹29,925 million for H1, while consolidated profit after tax surged nearly 76% to ₹6,885 million (vs ₹3,914 million a year ago), helped by lower losses at overseas subsidiaries. On a standalone basis, revenue rose modestly to ₹21,130 million and PAT grew 13% to ₹5,713 million for H1. Standalone EPS for Q2 came in at ₹18.33 vs ₹17.10 a year ago. The company granted ~8.6 lakh ESOPs during the half-year (₹199 million charge), and ended the period with a strong cash balance of ₹27,039 million and negligible debt on the books.
The sharp jump in consolidated H1 profits and a clean auditor review should be viewed positively by shareholders. However, the headline PAT surge is partly driven by shrinking losses at the French Cenexi subsidiaries rather than strong top-line growth, so investors should watch whether core margins and revenue momentum improve in coming quarters.